Invention Grant
- Patent Title: Optimized high-dose mesalazine-containing tablet
-
Application No.: US15770569Application Date: 2016-10-21
-
Publication No.: US11135159B2Publication Date: 2021-10-05
- Inventor: Rudolph Wilhelm , Markus Pröls , Roland Greinwald , Tanju Nacak
- Applicant: Dr. Falk Pharma GmbH
- Applicant Address: DE Freiburg
- Assignee: Dr. Falk Pharma GmbH
- Current Assignee: Dr. Falk Pharma GmbH
- Current Assignee Address: DE Freiburg
- Agency: Curatolo Sidoti Co., LPA
- Agent Salvatore A. Sidoti; Brittany L. Kulwicki
- Priority: EP15192269 20151030
- International Application: PCT/EP2016/075427 WO 20161021
- International Announcement: WO2017/072050 WO 20170504
- Main IPC: A61K9/20
- IPC: A61K9/20 ; A61K9/28 ; A61P1/00 ; A61K9/00 ; A61K31/606
Abstract:
The present invention relates to an oral enteric high-dose tablet comprising mesalazine as the active substance as well as its use.
Public/Granted literature
- US20180311155A1 OPTIMISED HIGH-DOSE MESALAZINE-CONTAINING TABLET Public/Granted day:2018-11-01
Information query
